Truveta Announces Strategic Collaboration with Pfizer to Accelerate Safety Insights in Real Time
21 juin 2022 09h07 HE | Truveta
BELLEVUE, Wash., June 21, 2022 (GLOBE NEWSWIRE) -- Truveta today announced a strategic collaboration with Pfizer to deliver new safety insights on a continuous basis, using verifiable real-world...
54741_Image_jpeg.jpg
Daxor’s Blood Volume Analyzer (BVA-100®) To Be Used As a Key Metric in Study of “Long Hauler” COVID-19 Patients
25 mai 2022 08h00 HE | Daxor Corporation
Oak Ridge, TN, May 25, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today participation in the National Institutes of...
Flow Therapy Adds World-Renowned Cardiologist Timothy D. Henry to Board of Directors
06 avr. 2022 09h00 HE | Flow Therapy
FORT WORTH, Texas, April 06, 2022 (GLOBE NEWSWIRE) -- World-renowned cardiologist Timothy D. Henry, MD, FACC, MSCAI, has joined Flow Therapy's Board of Directors. Dr. Henry is the Lindner Family...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive Interim Safety Assessment for Part 2 COVID-19 RESERVOIR Clinical Trial of Niclosamide for the Treatment of Gastrointestinal Infections
30 nov. 2021 07h00 HE | First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 30, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Logo-FullColour.png
Highmark Interactive Announces Collaboration with Mayo Clinic to Assess Impact of "Long COVID" on Cognitive Function
05 oct. 2021 11h30 HE | Highmark Interactive
TORONTO, Oct. 05, 2021 (GLOBE NEWSWIRE) -- BrainFx, a wholly owned subsidiary of Highmark Interactive, today announces its collaboration with Mayo Clinic to assess the impact of "Long COVID" or...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
10 sept. 2021 08h30 HE | AzurRx BioPharma, Inc.
BOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, therapies...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
09 sept. 2021 08h30 HE | AzurRx BioPharma, Inc.
Review of Interim Safety Data Concluded with Favorable Recommendation to Continue RESERVOIR Trial as Planned Part 2 of RESERVOIR Trial to Enroll Up to 150 Patients to Evaluate Efficacy of FW-1022 and...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
12 août 2021 07h00 HE | AzurRx BioPharma, Inc.
BOCA RATON, Fla., Aug. 12, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
07 juin 2021 07h00 HE | AzurRx BioPharma, Inc.
“RESERVOIR” trial to evaluate niclosamide’s ability to target SARS-CoV-2 in the GI tract Topline trial data expected in Q1 2022 BOCA RATON, Fla., June 07, 2021 (GLOBE NEWSWIRE) -- AzurRx...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections
09 févr. 2021 06h30 HE | AzurRx BioPharma, Inc.
Phase 2 Study of oral niclosamide planned for 1H 2021 DELRAY BEACH, Fla., Feb. 09, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage...